# Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer

> **NCT00498225** · PHASE3 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 834 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine plus TS-1
- **DRUG:** TS-1
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00498225
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-07
- **Final completion:** 2012-06
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2012-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498225, "Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00498225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*